Pulse Biosciences stock trades at EUR 48.80 late Thursday

Pulse Biosciences stock traded at 48.80 euros on Thursday, October 29, at 11:00 p.m. Berlin time, according to Lang & Schwarz. The quote provides a current market reference for the US medical technology company, while no verified Xetra closing comparison is available for this report.

Quarterly update ahead

Pulse Biosciences has scheduled the release of its third-quarter 2026 financial results and business update for November 5 after the US market close. The company's Investor Relations page also lists a conference call for the same day.

Investors will be watching the update for information on commercial progress and the development of Pulse Biosciences' bioelectric medicine platform. The company says its CellFX System uses proprietary Nano-Pulse Stimulation technology designed to clear cells without thermally damaging surrounding non-cellular tissue.

Commercial and clinical focus

Pulse Biosciences is pursuing applications in dermatology and other medical fields. Its investor materials describe a utilization-based revenue model for the CellFX System, while the company continues to expand the clinical and commercial use of its technology.

For investors, the upcoming update may provide further context on adoption, clinical development and the resources required to advance the platform. The scheduled event itself does not establish a forecast or guarantee a particular market reaction.

Investors can follow the real-time quote of Pulse Biosciences stock for subsequent price information.

Market conditions for US equities can be followed through the S&P 500 market overview.

More company-specific coverage is available in more news and analyses on Pulse Biosciences stock.